Corient Private Wealth
MRNA icon

Corient Private Wealth’s Moderna MRNA Stock Holding History

Corient Private Wealth’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.97M Buy
56,627
+1,916
+4% +$99.1K 0.01% 999
2026
Q1 		$2.77M Buy
54,711
+19,906
+57% +$929K ﹤0.01% 1094
2025
Q4 		$1.03M Buy
34,805
+6,751
+24% +$183K ﹤0.01% 1499
2025
Q3 		$725K Sell
28,054
-28,346
-50% -$791K ﹤0.01% 1592
2025
Q2 		$1.54M Buy
56,400
+34,354
+156% +$905K ﹤0.01% 1160
2025
Q1 		$625K Buy
22,046
+3,508
+19% +$124K ﹤0.01% 1495
2024
Q4 		$771K Sell
18,538
-14,459
-44% -$691K ﹤0.01% 1430
2024
Q3 		$2.21M Buy
32,997
+2,604
+9% +$239K ﹤0.01% 1055
2024
Q2 		$3.61M Buy
30,393
+2,561
+9% +$324K 0.01% 806
2024
Q1 		$2.97M Buy
27,832
+4,150
+18% +$418K 0.01% 854
2023
Q4 		$2.36M Buy
23,682
+2,855
+14% +$240K ﹤0.01% 931
2023
Q3 		$2.15M Sell
20,827
-3,597
-15% -$401K 0.01% 883
2023
Q2 		$2.97M Sell
24,424
-9,416
-28% -$1.26M 0.01% 780
2023
Q1 		$5.2M Sell
33,840
-1,185
-3% -$195K 0.01% 584
2022
Q4 		$6.29M Buy
+35,025
New +$5.73M 0.02% 443

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Corient Private Wealth's MRNA Position: Q2 2026 in Review

Corient Private Wealth increased its Moderna (MRNA) stake by 3.5% in Q2 2026, buying an estimated $99.1K and bringing the position to 56,627 shares worth $3.97M. The position accounts for 0.01% of the portfolio, ranked #999.

Corient Private Wealth first reported a position in MRNA in Q4 2022 and has held it in 15 quarters since. The position peaked at $6.29M in Q4 2022. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Corient Private Wealth held 56,627 shares of Moderna worth $3.97M as of Q2 2026.
  • Corient Private Wealth bought 1,916 Moderna shares in Q2 2026, an estimated $99.1K.
  • Moderna made up 0.01% of Corient Private Wealth's portfolio in Q2 2026, its #999 holding.
  • Corient Private Wealth first reported a position in Moderna in Q4 2022 and has held it in 15 quarters since.
  • Corient Private Wealth's Moderna position peaked at $6.29M in Q4 2022.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.